A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Must have histologically confirmed squamous cell carcinoma or adenosquamous cell
carcinoma of esophagus

- Male or Female at least 18 years of age

- Must have esophageal cancer that cannot be operated on, or treated with definitive
chemoradiation with curative intent, that is advanced, reoccurring or has spread out

- Must have full activity or, if limited, must be able to walk and carry out light
activities such as light house work or office work

- Must agree to provide tumor tissue sample, either from a previous surgery or biopsy
within 6 months or fresh, prior to the start of treatment in this study

Exclusion Criteria

- Presence of tumor cells in the brain or spinal cord which are symptomatic or require
treatment

- Active known or suspected autoimmune disease

- Any serious or uncontrolled medical disorder or active infection

- Known history of positive test for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS)

- Any positive test result for hepatitis B or C indicating acute or chronic infection
and/or detectable virus

Other protocol defined inclusion/exclusion criteria could apply